Skip to main content
Fig. 1 | Journal of Neuroinflammation

Fig. 1

From: Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson’s disease

Fig. 1

Overall research flow to select a drug candidate. Dataset provided by NHIS was divided into antihistamine-exposed and antihistamine-unexposed groups according to their prescription records. Each group’s LEDD before and after the index date was compared. NHIS-PD National Health Insurance System-Parkinson’s Disease, PD Parkinson’s disease, ATH antihistamines, PSM propensity score matching, Dx diagnosis, LEDD levodopa equivalent daily dose, n number of patients

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094